Literature DB >> 24604970

Hand foot syndrome associated with standard dose cytarabine.

Atul Sharma1, Saphalta Baghmar1.   

Abstract

Hand-foot syndrome, is a side effect of cytotoxic chemotherapy, causes erythema, dysthesias, swelling of palms and soles and sometimes blisters. Rarely, it may ulcerate. The most commonly used drug that frequently causes this reaction is 5-fluorouracil or its prodrug oral capecitabine. High dose cytarabine is known to cause HFS. Here we report a case of HFS caused by standard dose cytarabine.

Entities:  

Keywords:  Cytarabine; hand-foot syndrome; palmar-plantar erythrodysesthesia

Year:  2013        PMID: 24604970      PMCID: PMC3932608          DOI: 10.4103/0971-5851.125263

Source DB:  PubMed          Journal:  Indian J Med Paediatr Oncol        ISSN: 0971-5851


A 28-year-old lady with an acute myeloid leukemia underwent induction chemotherapy consisting of daily intravenous infusion of cytarabine (100 mg/m2) for 7-days plus daunorubicin (75 mg/m2) for 3 days. On day 8 of therapy the patient's left palm and soles became red and painful. Later, well-demarcated erythematous plaques, bullae, and desquamation developed over her hands and feet [Figure 1a and b]. Diagnosed as cytarabine-induced palmar-plantar erythrodysesthesia (hand foot syndrome, HFS, acral erythema, or Burgdorf's reaction). She was given supportive care, topical emollient, cushioning sore skin with soft pads and pyridoxine (vitamin B6), and the acral erythema completely resolved by day 18.
Figure 1a

Erythematous plaques, bullae, and desquamation of hand

Figure 1b

Discoloration of feet

Erythematous plaques, bullae, and desquamation of hand Discoloration of feet
  1 in total

1.  Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction.

Authors:  Maria Tavakoli-Ardakani; Shirin Haghighi; Shervin Shokouhi; Bahareh Abtahi-Naeini; Mohsen Meidani; Rezvan Hassanpour; Ali Saffaei
Journal:  Eurasian J Med       Date:  2019-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.